Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET program that is evaluating the investigational anti-OX40 therapy ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of eczema, known as atopic dermatitis, is characterized by persistent itching ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that rocatinlimab improves outcomes in atopic dermatitis, but questions about ...

Lilly hopes that "patients see themselves reflected in the commercial," says Ashley Diaz-Granados, SVP of U.S. immunology ...

While the IGNITE study evaluated rocatinlimab as monotherapy for 24 weeks, the SHUTTLE study evaluated the drug in combination with topical corticosteroids (TCS) and/or topical calcineurin ...

NIH researchers define diagnostic criteria for topical steroid withdrawal (TSW), distinguishing it from eczema.

Despite multiple treatments for eczema and pityriasis alba, a child’s skin condition worsened until a biopsy revealed mycosis ...